Gefitinib Enrolling by Invitation Phase 3 Trials for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03787992Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)